Healthcare
Zura Bio Limited(ZURA)
Live Price
Offline$3.75
+3.59% today
1Y Change
+234.82%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $350.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -76.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zura Bio Limited (ZURA) is a Healthcare stock with a market cap of $350.00M and listed on NASDAQ. The stock last traded around $3.75 and up 234.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -76.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -76.7%, free cash flow -130.6% with operating margin 0.0% and ROIC -74.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZURA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -76.7%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.3% | -8.1% | -23.4% |
2026 Mar 19, 2026 | -172.2% | -10.1% | -1.3% | -5.1% |
2025 Nov 13, 2025 | -10.5% | -2.4% | -12.2% | -3.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZURA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZURA Max Drawdown
-51.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZURA and SPY.
Company Overview
Zura Bio Limited
NASDAQ Capital Market
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
- Leadership
- Sandeep C. Kulkarni
- IPO Date
- Mar 21, 2023
- Employees
- 30
- Street Address
- 4225 Executive Square
- Mailing
- San Diego, CA, 92037
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 247 0520
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.9
Growth
- Revenue
- 0.0%
- EPS
- -76.7%
- Free Cash Flow
- -130.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -83.9%
- ROIC
- -74.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 9.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.